粒细胞集落刺激因子治疗肾移植后白细胞减少症

目的：评价重组人粒细胞集落刺激因子（Ｇ＿ＣＳＦ）在治疗肾移植后白细胞减少症中的效果及安全性。方法：应用Ｇ＿ＣＳＦ治疗肾移植后白细胞减少症１０例（男性６例，女性４例，年龄３８±ｓ１１ａ），每例注射Ｇ＿ＣＳＦ１５０μｇ，ｓｃ，ｑｄ，直至白细胞计数＞４×１０９／Ｌ。结果：１０例接受Ｇ＿ＣＳＦ的剂量为２２５±１０６μｇ，治疗前白细胞计数基值为（２．２±０．４）×１０９／Ｌ，治疗后白细胞峰值为（１０．６±２．６）×１０９／Ｌ（Ｐ＜０．０１），开始治疗至出现峰值时间为３．６±１．３ｄ，治疗前血清肌酐为２３５±１３５μｍｏｌ／Ｌ，治疗后２ｗｋ内最高血清肌酐为２３４±１２５μｍｏｌ／Ｌ（Ｐ＞０．０５）。结论：Ｇ＿ＣＳＦ治疗肾移植后白细胞减少症疗效显著，且不引起排斥反应

Granulocyte colony-stimulating factor for treatment of leukopenia in renal allograft recipients

AIM: To study the therapeutic effects and the safety of granulocyte colony-stimulating factor (G-CSF) in treating renal allograft recipients with leukopenia. METHODS: Ten patients (M6, F4; age 38±s 11 a) with leukopenia after kidney transplantation were treated with G-CSF 150 μg, sc, qd until the desired WBC count of >4×109/L was achieved. RESULTS: Ten patients received 225±106 μg G-CSF. The mean WBC nadir was (2.2±0.4)×109/L with peak WBC count of (10.6±2.6)×109/L following treatment(P<0.01). The time to peak WBC after initiation of treatment was 3.6±1.3 d. The mean pretreatment serum creatinine level was 235±135 μmol/L and peak serum creatinine in 2 wk following treatment was 234±125 μmol/L (P>0.05). CONCLUSION: G-CSF is an effective treatment for leukopenia in kidney transplant patients and does not precipitate or aggravate allograft rejection.